EVALUATIVE PROCEDURES TO DETECT, CHARACTERIZE, AND ASSESS THE SEVERITY OF DIABETIC NEUROPATHY

被引:16
作者
DYCK, PJ
机构
[1] Mayo Clinic, Mayo Foundation, Rochester, Minnesota
关键词
DIABETIC NEUROPATHY; STAGING; DIAGNOSTIC CRITERIA;
D O I
10.1111/j.1464-5491.1991.tb02156.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Minimal criteria for diabetic neuropathy need to be defined and universally applied. Standardized evaluative procedures need to be agreed and normal ranges determined from healthy volunteers. Types and stages of neuropathy should be established and assessments performed on representative populations of both Type 1 and Type 2 diabetic patients. Potential minimal criteria include absent ankle reflexes and vibratory sensation, and abnormalities of nerve conduction. However, the preferred criterion is the identification of more than two statistically defined abnormalities among symptoms and deficits, nerve conduction, quantitative sensory examination or quantitative autonomic examination. Various evaluative procedures are available. Symptoms should be assessed and scores can be assigned to neurological deficits. However, assessments of nerve conduction provide the most specific, objective, sensitive, and repeatable procedures, although these may be the least meaningful. Many techniques are available for quantitative sensory examination, but are poorly standardized and normal values are not available. For quantitative autonomic examination, tests are available for the adequacy of cardiovascular and peripheral vascular reflexes and increasingly for other autonomic functions. In any assessment of nerve function the conditions should be optimized and standardized, and stimuli defined. Specific instructions should be given and normal ranges established in healthy volunteers.
引用
收藏
页码:S48 / S51
页数:4
相关论文
共 14 条
[1]  
Thomas PK, Eliasson SG., Diabetic neuropathy, Peripheral Neuropathy, pp. 1773-1810, (1984)
[2]  
Melton LJ, Dyck PJ., Epidemiology, Diabetic Neuropathy, pp. 27-35, (1987)
[3]  
Gilliatt RW., Clinical aspects of diabetic neuropathy, Biochemical Aspects of Neurological Disorders, pp. 117-142, (1965)
[4]  
Pirart J., Diabetic neuropathy: A metabolic or a vascular disease?, Diabetes, 14, pp. 1-9, (1965)
[5]  
Dyck PJ, Bushek W., Spring E., Et al., Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy, Diabetes Care, 10, pp. 432-440, (1987)
[6]  
Dyck PJ., Detection, characterization, and staging of polyneuropathy: assessed in diabetics, Muscle Nerve, 11, pp. 21-32, (1988)
[7]  
Dyck PJ, Karnes JL, Daube J., O'Brien P., Service FJ., Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy, Brain, 108, pp. 861-880, (1985)
[8]  
Melzack R., The McGill pain questionnaire: major properties and scoring methods, Pain, 1, pp. 277-299, (1975)
[9]  
Dyck PJ, Sherman WR, Hallcher LM, Et al., Human diabetic endothelial sorbial, fructose and myo‐inositol related to sural nerve morphometry, Ann Neurol, 8, pp. 590-596, (1980)
[10]  
Dyck PJ, Karnes J., O'Brien PC, Swanson CJ., Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy and amyloidosis, Neurology, 36, pp. 1300-1308, (1986)